Antivirals - Post-Approval Insights
Antiviral drug approvals over the last decade have been dominated by drugs aimed at treating Hepatitis C (HCV) and human immunodeficiency virus (HIV). An estimated 2.4 million to 4.7 million people are living with HCV in the US, while about 1.2 million people in the US live with HIV.
Leveraging Data Analytics to Boost Pharmaceutical Market Access
Specialty drugs comprise a growing share of the pharmaceutical market. According to an industry report by Drug Channels, total prescription revenues surpassed $500 billion in 2021, with specialty drugs accounting for almost 40 percent of outpatient prescription revenues and an even larger share of payers’ net prescription costs. Over the next five years, these therapies are projected to account for at least half of all revenue generated by the pharmacy industry.
3 Ways a Patient Access Platform Breaks Through Barriers to Medication
There was a time when the path from a physician prescribing to the patient starting drug therapy was straightforward. With the rise of value-based healthcare and novel specialty treatments, that’s no longer the case.
How to choose the best commercialization partner to drive patient access
Is a pharmaceutical hub the best solution for commercializing your therapies? For well over a decade, pharmaceutical hub services have played a pivotal role in supporting patient access to life-saving and life-altering advanced drug therapies. Unfortunately, hubs tend to be a partner with low customer satisfaction rates and lower than ideal coverage and adherence. So, what is the best way to support patient access to critical therapies?
Case Study: Defying the Mid-Cycle Curse for Specialty Pharma
Mid-cycle specialty products often face challenges when it comes to reaching patients several years after launch.
What if you could decrease time to therapy from 7 days to 1 day?
Healthcare tech and existing hub services offer solutions for patients trying to access specialty pharmaceuticals, but they are falling short when it comes to reaching eligible patients, keeping them adherent to therapy. While digital and specialty pharmacies have attempted to circumvent many access issues, patients still face roadblocks when it comes to limited networks, plan coverage, and complex prior-authorization protocols leaving the average time to therapy hovering around 7 days. Even new digital pharmacies deter patient enrollment, causing script abandonment and impeding potential prescribing volumes.